

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/585,562	ATTY. DOCKET NO.: Y0087.70013US01
				FILING DATE: March 6, 2007	CONFIRMATION NO.: 4715
				APPLICANT: Tony George	
				GROUP ART UNIT: 1617	
Sheet	1	of	2	EXAMINER: S.J. Jean-Louis	

U.S. PATENT DOCUMENTS

Examiner's Initials #	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
	A2	6,197,827	B1	Cary et al.	03-06-2001
	A3	6,734,215	B2	Shytle et al.	05-11-2004
	A4	6,979,698	B1	Sandberg et al.	12-27-2005
	A5	7,101,916	B2	Shytle et al.	09-05-2006
	A6	US 2006-0276551	A1	Al Shytle et al.	12-07-2006
	A7	6,034,079		Sanberg et al.	03-07-2000

FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	C4	BENCHERIF et al., Targeting Neuronal Nicotinic Receptors: a Path to New Therapies. <i>Curr Drug Targets CNS Neurol Disord.</i> 2002 Aug;1(4):349-57.	
	C5	FEDOROV et al., Differential Pharmacologies of Mecamylamine Enantiomers: Positive Allosteric Modulation and Non-Competitive Inhibition. <i>J Pharmacol Exp Ther.</i> 2008 Oct 28. pp. 1-39. DOI: 10.1124/jpet.108.146910.	
	C6	LIPPIELLO, P.M., Nicotinic cholinergic antagonists: A novel approach for the treatment of autism. <i>Med Hypotheses.</i> 2006;66(5):985-90.	
	C7	LIPPIELLO et al., TC-5214 (S-(+)-Mecamylamine): A Neuronal Nicotinic Receptor Modulator with Antidepressant Activity. <i>CNS Neurosci Ther.</i> 2008 Winter;14(4):266-77	
	C8	McCONVILLE et al., The Effects of Nicotine Plus Haloperidol Compared to Nicotine Only and Placebo Nicotine Only in Reducing Tic Severity and Frequency in Tourette's Disorder. <i>Biol Psychiatry.</i> 1992 Apr 15;31(8):832-40.	
	C9	McCONVILLE et al., Nicotine Potentiation of Haloperidol in Reducing Tic Frequency in Tourette's Disorder. <i>Am J Psychiatry.</i> 1991 Jun;148(6):793-4.	
	C10	MA, et al., Evidence of reuptake inhibition responsible for mecamylamine-evoked increases in extracellular serotonin. <i>Brain Res.</i> 2006 Feb 16;1073-1074.	
	C11	NEWMAN et al., Anxiolytic Effects of Mecamylamine in Two Animal Models of Anxiety. <i>Exp Clin Psychopharmacol.</i> 2002 Feb;10(1):18-25.	
	C12	NEWMAN et al., Corticosterone-Attenuating and Anxiolytic Properties of Mecamylamine in the rat. <i>Prog Neuropsychopharmacol Biol Psychiatry.</i> 2001 Apr;25(3):609-20.	
	C13	NEWMAN et al., Nicotine induced seizures blocked by mecamylamine and its stereoisomers. <i>Life Sci.</i> 2001 Oct 19;69(22):2583-91.	
	C14	PAPKE et al., Analysis of Mecamylamine Stereoisomers on Human Nicotinic Receptor Subtypes. <i>J Pharmacol Exp Ther.</i> 2001 May;297(2):646-56.	
	C15	SANBERG et al., Nicotine Potentiation of Haloperidol-Induced Catalepsy: Striatal Mechanisms. <i>Pharmacol Biochem Behav.</i> 1993 Oct;46(2):303-7.	
	C16	SCHÖNENBERGER et al., Preparation of Optically Active Secondary Amines by Thermal Decomposition of (Methylbenzyl)urea Analogs: Absolute Configuration of (+)- and (-)-Mecamylamine. <i>Helvetica Chimica Acta.</i> 1986 Vol. 69: 283-7.	

FORM PTO-1449/A and B (modified PTO/SB/08)			APPLICATION NO.: 10/585,562	ATTY. DOCKET NO.: Y0087.70013US01
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			FILING DATE: March 6, 2007	CONFIRMATION NO.: 4715
			APPLICANT: Tony George	
Sheet	2	of	2	GROUP ART UNIT: 1617 EXAMINER: S.J. Jean-Louis

C17	SHYTLE et al., Comorbid Bipolar Disorder in Tourette's syndrome Responds to the Nicotine Receptor Antagonist Mecamylamine (Inversine). <i>Biol Psychiatry</i> . 2000 Nov 15;48(10):1028-31.	
C18	SHYTLE et al., Mecamylamine (Inversine®): an old antihypertensive with new research directions. <i>J Hum Hypertens</i> . 2002 Jul;16(7):453-7.	
C19	SHYTLE et al., Neuronal Nicotinic Receptor Inhibition For Treating Mood Disorders: Preliminary Controlled Evidence with Mecamylamine. <i>Depress Anxiety</i> . 2002;16(3):89-92.	
C20	SHYTLE et al., Nicotinic acetylcholine receptors as targets for antidepressants. <i>Mol Psychiatry</i> . 2002;7(6):525-35.	
C21	SUCHOCKI et al., Synthesis of 2-exo-and 2-endo-Mecamylamine Analogues. Structure-Activity Relationships for Nicotinic Antagonism in the Central Nervous System. <i>J Med Chem</i> . 1991 Mar;34(3):1003-10.	
C22	YOUNG et al., Mecamylamine: New Therapeutic Uses and Toxicity/Risk Profile. <i>Clin Ther</i> . 2001 Apr;23(4):532-65.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. ___, filed ___, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]